- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03797703
Efficacy of Lidocaine Gel Enema After Endoscopic Hemorrhoid Band Ligation for Relief of Post Procedural Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective single center study to evaluate side effects and efficacy of a lidocaine jelly 2% enema following endoscopic hemorrhoid band ligation. The investigators will administer a single dose of 15 mL lidocaine jelly 2%, obtained from Advocate main pharmacy, as an enema immediately post procedure. Patients will not be permitted to self-administer additional doses following discharge.
Prior to being enrolled in the study, the clinician will perform a Comprehensive Metabolic Panel and Complete Blood Count. When appropriate, a urine pregnancy test will be performed prior to enrollment. The investigators will assess for any signs or symptoms of liver disease. These assessments will occur within one month of the procedure date. If the patient has any signs of renal or hepatic impairment (creatinine greater than 2 or Childs Pugh Class 3), they will be excluded from the study. The researchers will also exclude patients with any history of arrhythmias or who are currently on anti-arrhythmic medications. Once the patient is deemed safe to proceed, the lidocaine gel enema will be placed at the cessation of the procedure by the investigator. At the time of the procedure, the clinician will assess and use their best judgement to determine if the rectal mucosa is generally intact by visual inspection. If the mucosa remains intact, the subject will be able to be included in the study. However, if the rectal mucosa is traumatized the subject will be excluded and will not participate in the randomized treatment.
Following the procedure, the patient will be monitored closely with a one-on one registered nurse for 4 hours in an observation unit. Vital signs will be taken every 5 minutes, as well as continuous EKG monitoring and pulse oximetry monitoring. If any adverse side effects occur, the physician is immediately available for further management and admission to the hospital if needed. Upon completion of the 4-hour observation period, the participants will be evaluated by a registered nurse and physician prior to discharge home following the procedure. The patient will be discharged with a responsible adult who will care for the patient for 24 additional hours. The clinician will communicate with the patient and responsible adult regarding any adverse side effects. The patient will also receive a phone number to call to reach the physician or the physician's associate who will be able to verbally assist the patient immediately should any adverse events occur.
For data collection, one hour following the procedure a clinician will screen for any adverse side effects and pain will be assessed using a numeric pain scale (0-10). The patient will also be contacted via telephone to assess adverse side effects and pain scale at 24 hours and 48 hours post procedure. The investigators will also call the patient at 72 to 96 hours to assess for any adverse effects. The patients will be followed up by the principal investigator for routine check-ups following the procedure. The clinician will be easily accessible via telephone and the patient will be given instructions on how to contact the clinician, if needed.
Data to be collected on each subject will include: date of procedure, specific patient ID, gender, age, internal hemorrhoids grade, race (White, African American, Hispanic, Asian), BMI, comorbid conditions, pain 1 hour post procedure, pain 24 and 48 hours post procedure, requirement of narcotic pain medication, requirement of other oral analgesic medication, sedation utilized and complications or adverse side effects from the medication.
Upon data collection of this trial, we will monitor for any adverse events. If there is an adverse event that is deemed by the principal investigator likely due to drug administration, we will report it to the FDA immediately through written communication and an IND Safety Report. It will be reported within at least 7 calendar days of being notified of the adverse event.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Advocate Christ Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients older than 18 years of age
- Patients undergoing endoscopic hemorrhoid band ligation at Advocate Christ Medical Center
Exclusion Criteria:
- Patients undergoing endoscopic hemorrhoids band ligation who are already on pain medications chronically due to other reasons
- Patients with moderate to severe renal impairment, defined as creatinine greater than 2
- Patients with hepatic dysfunction, defined as patients with signs or symptoms of liver dysfunction and/or patients with Childs Pugh Class C
- Patients with any history of arrhythmias or are currently on anti-arrhythmic medications
- Patients with any contraindications to lidocaine, including hypersensitivity to local anesthetics of the amide type or any other component within the lidocaine 2% jelly
- Patients with traumatized rectal mucosa in the area of application at the time of the procedure
- Patients who are currently pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Patients will be randomly allocated into the treatment group.
The treatment group will receive a 15 mL lidocaine gel enema rectally immediately following completion of the procedure.
|
Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
|
No Intervention: Control
Patients will be randomly allocated into the control group.
The control group will not receive a rectal enema.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pain following Procedure at 1 hour, 24 hours and 48 hours
Time Frame: This information will be collected at 1 hour, 24 hours and 48 hours after the procedure.
|
This effect will be measured by statistical analysis comparing the treatment groups numeric pain scale ratings (0-10) with the control groups numeric pain scale ratings (0-10).
|
This information will be collected at 1 hour, 24 hours and 48 hours after the procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Medication Needs
Time Frame: This will be evaluated 48 hours after the procedure.
|
This effect will be measured by asking the subject what pain medication was needed following the procedure and the amount taken.
|
This will be evaluated 48 hours after the procedure.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Pain
- Neurologic Manifestations
- Gastrointestinal Diseases
- Intestinal Diseases
- Rectal Diseases
- Pain, Procedural
- Hemorrhoids
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- AHC-6999-M5000223
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhoids
-
Vilnius UniversityBiolitec Pharma Ltd.UnknownHemorrhoids Second Degree | Hemorrhoids Third DegreeLithuania
-
Ventrus Biosciences, IncTerminatedInternal HemorrhoidsUnited States
-
Societa Italiana di Chirurgia ColoRettaleSICCR - Gaetano GalloCompletedSecond-degree HemorrhoidsItaly
-
Nivagen Pharmaceuticals Inc.CompletedInternal HemorrhoidsUnited States, India
-
Universidade do PortoCompletedHemorrhoids, InternalPortugal
-
G & W Laboratories Inc.CompletedInternal HemorrhoidsUnited States
-
Kuwait Oil Company Ahmadi HospitalNetherlands: Ministry of Health, Welfare and SportsCompleted
-
Services Hospital, LahoreCompletedLength of Stay | Operative Time | Hemorrhoidectomy | Third Degree Hemorrhoids | Fourth Degree Hemorrhoids | Postoperative,PainPakistan
-
BayerCompletedAcute HemorrhoidsRussian Federation
-
Proctos KliniekRecruitingRectal Diseases | Hemorrhoids | PROM | Hemorrhoids, InternalNetherlands
Clinical Trials on Lidocaine Hydrochloride 2% gel enema
-
Stanford UniversityCompleted
-
Taro Pharmaceuticals USACompleted
-
University of Southern CaliforniaCompletedPelvic Floor DisordersUnited States
-
Second Xiangya Hospital of Central South UniversityWithdrawn
-
University of Alabama at BirminghamCompletedValue of the Bowel Preparation and Diet Change Versus no Intervention | Preoperative Bowel RegimenUnited States
-
Oregon Health and Science UniversityCompleted
-
Sol-Gel Technologies, Ltd.TerminatedBasal Cell Nevus SyndromeUnited States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
University of OklahomaWithdrawnPain Perception | PhlebotomyUnited States